Frontiers in Immunology (Sep 2024)
Cytosolic nucleic acid sensors and interferon beta-1 activation drive radiation-induced anti-tumour immune effects in human pancreatic cancer cells
- Sylvia Kerschbaum-Gruber,
- Sylvia Kerschbaum-Gruber,
- Sylvia Kerschbaum-Gruber,
- Ava Kleinwächter,
- Ava Kleinwächter,
- Ava Kleinwächter,
- Ava Kleinwächter,
- Ava Kleinwächter,
- Katerina Popova,
- Katerina Popova,
- Katerina Popova,
- Alexandra Kneringer,
- Alexandra Kneringer,
- Alexandra Kneringer,
- Lisa-Marie Appel,
- Lisa-Marie Appel,
- Lisa-Marie Appel,
- Lisa-Marie Appel,
- Katharina Stasny,
- Anna Röhrer,
- Anna Röhrer,
- Anna Röhrer,
- Ana Beatriz Dias,
- Ana Beatriz Dias,
- Ana Beatriz Dias,
- Ana Beatriz Dias,
- Johannes Benedum,
- Johannes Benedum,
- Johannes Benedum,
- Johannes Benedum,
- Johannes Benedum,
- Lena Walch,
- Lena Walch,
- Andreas Postl,
- Andreas Postl,
- Andreas Postl,
- Sandra Barna,
- Sandra Barna,
- Sandra Barna,
- Bernhard Kratzer,
- Winfried F. Pickl,
- Winfried F. Pickl,
- Altuna Akalin,
- Filip Horvat,
- Filip Horvat,
- Vedran Franke,
- Joachim Widder,
- Joachim Widder,
- Dietmar Georg,
- Dietmar Georg,
- Dietmar Georg,
- Dea Slade,
- Dea Slade,
- Dea Slade,
- Dea Slade,
- Dea Slade
Affiliations
- Sylvia Kerschbaum-Gruber
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Sylvia Kerschbaum-Gruber
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Sylvia Kerschbaum-Gruber
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
- Ava Kleinwächter
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Ava Kleinwächter
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Ava Kleinwächter
- Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna, Austria
- Ava Kleinwächter
- Center for Medical Biochemistry, Medical University of Vienna, Vienna, Austria
- Ava Kleinwächter
- Vienna Biocenter PhD Program, a Doctoral School of the University of Vienna and the Medical University of Vienna, Vienna, Austria
- Katerina Popova
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Katerina Popova
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Katerina Popova
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
- Alexandra Kneringer
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Alexandra Kneringer
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Alexandra Kneringer
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
- Lisa-Marie Appel
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Lisa-Marie Appel
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Lisa-Marie Appel
- Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna, Austria
- Lisa-Marie Appel
- Center for Medical Biochemistry, Medical University of Vienna, Vienna, Austria
- Katharina Stasny
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
- Anna Röhrer
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Anna Röhrer
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Anna Röhrer
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
- Ana Beatriz Dias
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Ana Beatriz Dias
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Ana Beatriz Dias
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
- Ana Beatriz Dias
- Vienna Biocenter PhD Program, a Doctoral School of the University of Vienna and the Medical University of Vienna, Vienna, Austria
- Johannes Benedum
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Johannes Benedum
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Johannes Benedum
- Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna, Austria
- Johannes Benedum
- Center for Medical Biochemistry, Medical University of Vienna, Vienna, Austria
- Johannes Benedum
- Vienna Biocenter PhD Program, a Doctoral School of the University of Vienna and the Medical University of Vienna, Vienna, Austria
- Lena Walch
- Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna, Austria
- Lena Walch
- Center for Medical Biochemistry, Medical University of Vienna, Vienna, Austria
- Andreas Postl
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Andreas Postl
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Andreas Postl
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
- Sandra Barna
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Sandra Barna
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Sandra Barna
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
- Bernhard Kratzer
- Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Vienna, Austria
- Winfried F. Pickl
- Center for Pathophysiology, Infectiology and Immunology, Institute of Immunology, Medical University of Vienna, Vienna, Austria
- Winfried F. Pickl
- Karl Landsteiner University of Health Sciences, Krems, Austria
- Altuna Akalin
- Max Delbrück Center, The Berlin Institute for Medical Systems Biology, Berlin, Germany
- Filip Horvat
- Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna, Austria
- Filip Horvat
- Center for Medical Biochemistry, Medical University of Vienna, Vienna, Austria
- Vedran Franke
- Max Delbrück Center, The Berlin Institute for Medical Systems Biology, Berlin, Germany
- Joachim Widder
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Joachim Widder
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Dietmar Georg
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Dietmar Georg
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Dietmar Georg
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
- Dea Slade
- Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria
- Dea Slade
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- Dea Slade
- MedAustron Ion Therapy Center, Wiener Neustadt, Austria
- Dea Slade
- Max Perutz Labs, Vienna Biocenter Campus (VBC), Vienna, Austria
- Dea Slade
- Center for Medical Biochemistry, Medical University of Vienna, Vienna, Austria
- DOI
- https://doi.org/10.3389/fimmu.2024.1286942
- Journal volume & issue
-
Vol. 15
Abstract
IntroductionPancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer-related deaths worldwide with limited treatment options due to extensive radiation and chemotherapy resistance. Monotherapy with immune checkpoint blockade showed no survival benefit. A combination of immunomodulation and radiotherapy may offer new treatment strategies, as demonstrated for non-small cell lung cancer. Radiation-induced anti-tumour immunity is mediated through cytosolic nucleic acid sensing pathways that drive the expression of interferon beta-1 (IFNB1) and proinflammatory cytokines.MethodsHuman PDAC cell lines (PANC-1, MIA PaCa-2, BxPC-3) were treated with X-rays and protons. Immunogenic cell death was measured based on HMGB1 release. Cytosolic dsDNA and dsRNA were analysed by immunofluorescence microscopy. Cell cycle progression, MHC-I and PD-L1 expression were determined by flow cytometry. Galectin-1 and IFNB1 were measured by ELISA. The expression levels and the phosphorylation status of the cGAS/STING and RIG-I/MAVS signalling pathways were analysed by western blotting, the expression of IFNB1 and proinflammatory cytokines was determined by RT-qPCR and genome-wide by RNA-seq. CRISPR-Cas9 knock-outs and inhibitors were used to elucidate the relevance of STING, MAVS and NF-κB for radiation-induced IFNB1 activation.ResultsWe demonstrate that a clinically relevant X-ray hypofractionation regimen (3x8 Gy) induces immunogenic cell death and activates IFNB1 and proinflammatory cytokines. Fractionated radiation induces G2/M arrest and accumulation of cytosolic DNA in PDAC cells, which partly originates from mitochondria. RNA-seq analysis shows a global upregulation of type I interferon response and NF-κB signalling in PDAC cells following 3x8 Gy. Radiation-induced immunogenic response is regulated by STING, MAVS and NF-κB. In addition to immunostimulation, radiation also induces immunosuppressive galectin-1. No significant changes in MHC-I or PD-L1 expression were observed. Moreover, PDAC cell lines show similar radiation-induced immune effects when exposed to single-dose protons or photons.ConclusionOur findings provide a rationale for combinatorial radiation-immunomodulatory treatment approaches in PDAC using conventional photon-based or proton beam radiotherapy.
Keywords